[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Donald Manning Biography and Net Worth

Insider of Pacira BioSciences

Donald Manning, M.D. Ph.D. has served as our Chief Medical Officer since May 2020. Prior to joining Pacira, he was the Chief Medical Officer of Adynxx, Inc., a biopharmaceutical company, from January 2012 to April 2020. Dr. Manning has also served as Chief Medical Officer at Shionogi Inc. from July 2009 to May 2011 and as Executive Vice President of Clinical Development, Medical Affairs and Pharmacovigilance from March 2010 to May 2011. Prior to Shionogi Dr. Manning held positions of increasing authority between 1998 and 2009 at King Pharmaceuticals, Alpharma Inc, Celgene and Novartis Pharmaceuticals. Dr. Manning received a B.Sc. from McGill University and a Ph.D. in Pharmacology and an M.D. at Johns Hopkins University. He pursued residency training in Anesthesiology, fellowship training in Regional Anesthesia and Pain Management and a Post-Doctoral Fellowship in the Department of Neurosurgery all at Johns Hopkins. Dr. Manning has held faculty positions in the Departments of Anesthesiology at Johns Hopkins, where he was co-director of the Pain Management Center and The University of Virginia Health Sciences Center where he founded the Women’s Pelvic Pain Center. Dr. Manning has lectured and published widely on pain management topics and is a past-president and current board member of the Eastern Pain Association.

What is Donald C. Manning's net worth?: The estimated net worth of Donald C. Manning is at least $433,592.00 as of June 2nd, 2021. Dr. Manning owns 26,120 shares of Pacira BioSciences stock worth more than $433,592 as of November 17th. This net worth estimate does not reflect any other investments that Dr. Manning may own. Learn More about Donald C. Manning's net worth.
How do I contact Donald C. Manning?: The corporate mailing address for Dr. Manning and other Pacira BioSciences executives is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. Pacira BioSciences can also be reached via phone at (813) 553-6680 and via email at [email protected]. Learn More on Donald C. Manning's contact information.
Has Donald C. Manning been buying or selling shares of Pacira BioSciences?: Donald C. Manning has not been actively trading shares of Pacira BioSciences over the course of the past ninety days. Most recently, Donald C. Manning sold 2,380 shares of the business's stock in a transaction on Wednesday, June 2nd. The shares were sold at an average price of $62.12, for a transaction totalling $147,845.60. Following the completion of the sale, the insider now directly owns 26,120 shares of the company's stock, valued at $1,622,574.40. Learn More on Donald C. Manning's trading history.
Who are Pacira BioSciences' active insiders?: Pacira BioSciences' insider roster includes Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.
Are insiders buying or selling shares of Pacira BioSciences?: In the last twelve months, Pacira BioSciences insiders bought shares 3 times. They purchased a total of 11,176 shares worth more than $136,240.40. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 113,661 shares worth more than $3,413,175.87. The most recent insider tranaction occured on September, 13th when COO Daryl Gaugler sold 500 shares worth more than $6,430.00. Insiders at Pacira BioSciences own 6.4% of the company. Learn More about insider trades at Pacira BioSciences.
Information on this page was last updated on 9/13/2024.

Donald C. Manning Insider Trading History at Pacira BioSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/2/2021	Sell	2,380	$62.12	$147,845.60	26,120

Donald C. Manning Buying and Selling Activity at Pacira BioSciences

Pacira BioSciences Company Overview

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Today's Range

Now: $16.60

$16.21

$16.66

50 Day Range

MA: $15.81

$12.73

$17.70

2 Week Range

Now: $16.60

$11.16

$35.95

Volume

780,465 shs

Average Volume

535,337 shs

Market Capitalization

$766.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82